WT1 inhibits AML cell proliferation in a p53-dependent manner

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• The Wilms Tumor 1 (WT1) gene has a dual role as an oncogene and tumor suppressor in acute myeloid leukemia (AML).
• The precise molecular mechanisms governing WT1's function in AML remain incompletely understood.
• The interplay between WT1 and the tumor suppressor p53 in AML pathogenesis requires further investigation.

Purpose of the Study:

• To elucidate the role of the tumor suppressor p53 in regulating WT1 function in AML.
• To investigate the molecular mechanisms underlying the controversial functions of WT1 in AML.
• To determine the impact of p53 mutations on WT1's activity in AML.

Main Methods:

• Meta-analysis of 1131 AML cases to assess the relationship between WT1 and TP53 gene mutations.
• Investigation of physical interactions between p53 and WT1.
• Assessment of p53's effect on WT1's ability to modulate target gene expression.
• Evaluation of the impact of wild-type and mutated p53 on WT1-mediated proliferation in AML cells.

Main Results:

• A mutually exclusive predisposition between WT1 gene mutations and TP53 gene mutations was observed in AML.
• p53 physically interacts with WT1 to modulate the expression of WT1's target genes.
• AML-derived p53 mutations (e.g., p53^R248Q) disrupt the p53-WT1 interaction, leading to loss of target gene modulation.
• Wild-type p53 maintains WT1's anti-proliferative activity in AML cells, whereas WT1 promotes proliferation in the absence of functional p53.

Conclusions:

• WT1's function in AML is dependent on the status of p53.
• p53 acts as a critical regulator of WT1, influencing its role in AML cell proliferation.
• This study provides a novel mechanism explaining WT1's context-dependent function in AML, highlighting the importance of p53.